Relay Therapeutics Ownership | Who Owns Relay Therapeutics?
Relay Therapeutics Ownership Summary
Relay Therapeutics is owned by 21.69% institutional investors, 1.57% insiders, and 76.74% retail investors. Sb investment advisers (uk) is the largest institutional shareholder, holding 16.29% of RLAY shares. BB Biotech AG Ord is the top mutual fund, with 4.41% of its assets in Relay Therapeutics shares.
RLAY Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Relay Therapeutics | 21.69% | 1.57% | 76.74% |
| Sector | Healthcare Stocks | 35.56% | 12.08% | 52.36% |
| Industry | Biotech Stocks | 35.43% | 12.01% | 52.56% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Sb investment advisers (uk) | 27.90M | 16.29% | $145.66M |
| Fmr | 20.11M | 11.18% | $376.26M |
| Commodore capital lp | 17.00M | 9.91% | $169.15M |
| Blackrock funding, inc. /de | 15.29M | 8.50% | $286.04M |
| Casdin capital | 14.42M | 8.40% | $143.46M |
| Blackrock | 10.54M | 7.94% | $68.74M |
| Perceptive advisors | 9.75M | 5.68% | $97.02M |
| State street | 10.13M | 5.63% | $189.47M |
| Vanguard group | 9.69M | 5.62% | $81.99M |
| Vanguard capital management | 8.96M | 4.98% | $167.72M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Casdin capital | 14.42M | 10.86% | $143.46M |
| Commodore capital lp | 17.00M | 9.79% | $169.15M |
| Foresite capital management iv | 1.00M | 4.20% | $9.95M |
| Nextech invest | 5.53M | 3.87% | $54.99M |
| Nextech invest | 3.85M | 2.57% | $15.85M |
| Perceptive advisors | 9.75M | 1.90% | $97.02M |
| Bellevue group | 7.80M | 1.85% | $77.56M |
| Bioimpact capital | 2.36M | 1.81% | $23.48M |
| Tfg asset management gp | 570.31K | 1.68% | $10.67M |
| Tang capital management | 8.07M | 1.62% | $42.12M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 20.11M | 0.02% | 16.41M |
| Perceptive advisors | 9.75M | 1.90% | 7.85M |
| State street | 10.13M | 0.01% | 3.89M |
| Siren | 3.65M | 1.38% | 3.65M |
| Westfield capital management co lp | 3.34M | 0.20% | 3.34M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Point72 asset management | - | - | -13.86M |
| Braidwell lp | - | - | -3.50M |
| Eventide asset management | - | - | -2.68M |
| Finepoint capital lp | - | - | -2.12M |
| Jacobs levy equity management | - | - | -1.68M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Siren | 3.65M | 1.38% | 3.65M | $68.29M |
| Westfield capital management co lp | 3.34M | 0.20% | 3.34M | $62.56M |
| Ecor1 capital | 1.90M | 0.80% | 1.90M | $18.95M |
| First trust advisors lp | 1.08M | 0.01% | 1.08M | $20.12M |
| Norges bank | 837.42K | 0.00% | 837.42K | $7.08M |
Sold Out
| Holder | Change |
|---|---|
| Tfc financial management | -1.00 |
| Aster capital management (difc) | -10.00 |
| Capital performance advisors llp | -11.00 |
| Nelson, van denburg & campbell wealth management group | -18.00 |
| First command advisory services | -25.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 123 | -46.05% | 37,220,983 | -78.55% | 21 | 0.21% | 66 | -44.07% | 31 | -45.61% |
| Dec 31, 2025 | 150 | -26.11% | 57,894,103 | -65.17% | 33 | 0.36% | 73 | -15.12% | 39 | -38.10% |
| Sep 30, 2025 | 192 | -3.52% | 164,241,668 | -1.23% | 95 | 1.02% | 79 | -25.47% | 63 | 26.00% |
| Jun 30, 2025 | 203 | -3.33% | 170,787,021 | 4.95% | 99 | 1.08% | 106 | -3.64% | 54 | -5.26% |
| Mar 31, 2025 | 13 | -93.60% | 21,465,711 | -86.91% | 12 | 0.09% | 8 | -93.89% | 2 | -94.44% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BB Biotech AG Ord | 7.38M | 4.41% | - |
| Vanguard Total Stock Mkt Idx Inv | 6.80M | 3.12% | -35.27K |
| Vanguard Morn Total Stk Mkt Idx Investor | 6.80M | 3.12% | -35.27K |
| Vanguard US Total Market Shares ETF | 4.89M | 2.88% | 904.00K |
| State Street® SPDR® S&P® Biotech ETF | 6.19M | 2.82% | 14.21K |
| iShares Russell 2000 ETF | 4.12M | 1.88% | -73.25K |
| Eventide Healthcare & Life Sciences I | 2.68M | 1.56% | - |
| JPMorgan Small Cap Growth A | 2.20M | 1.29% | 32.86K |
| SPDR® S&P Biotech ETF | 2.22M | 1.29% | 4.95K |
| Vanguard Small Cap Index | 2.02M | 1.18% | 7.50K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 28, 2026 | Catinazzo Thomas | Chief Financial Officer | Sell | $27.15K |
| Jul 28, 2026 | Rahmer Peter | See remarks | Sell | $13.92K |
| Jul 28, 2026 | Bergstrom Donald A | President, R&D | Sell | $41.63K |
| Jul 06, 2026 | Bergstrom Donald A | President, R&D | Sell | $162.03K |
| Jul 07, 2026 | Patel Sanjiv | President and CEO | Sell | $943.74K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 6 |
| 2026 Q2 | - | 10 |
| 2026 Q1 | - | 8 |
| 2025 Q4 | - | 5 |
| 2025 Q3 | - | 10 |
RLAY Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools